What is the share price of Hikal Ltd (HIKAL) today?
The share price of HIKAL as on 5th December 2025 is ₹242. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Hikal Ltd (HIKAL) share?
The past returns of Hikal Ltd (HIKAL) share are- Past 1 week: 10.23%
- Past 1 month: 0.48%
- Past 3 months: -2.64%
- Past 6 months: -33.27%
- Past 1 year: -42.71%
- Past 3 years: -26.21%
- Past 5 years: 47.46%
What are the peers or stocks similar to Hikal Ltd (HIKAL)?
The peers or stocks similar to Hikal Ltd (HIKAL) include:What is the dividend yield % of Hikal Ltd (HIKAL) share?
The current dividend yield of Hikal Ltd (HIKAL) is 0.32.What is the market cap of Hikal Ltd (HIKAL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Hikal Ltd (HIKAL) is ₹3118.15 Cr as of 5th December 2025.What is the 52 week high and low of Hikal Ltd (HIKAL) share?
The 52-week high of Hikal Ltd (HIKAL) is ₹456.75 and the 52-week low is ₹218.What is the PE and PB ratio of Hikal Ltd (HIKAL) stock?
The P/E (price-to-earnings) ratio of Hikal Ltd (HIKAL) is 34.34. The P/B (price-to-book) ratio is 2.47.Which sector does Hikal Ltd (HIKAL) belong to?
Hikal Ltd (HIKAL) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Hikal Ltd (HIKAL) shares?
You can directly buy Hikal Ltd (HIKAL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Hikal Ltd
HIKAL Share Price
242.004.31% (-10.89)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
HIKAL Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
HIKAL Performance & Key Metrics
HIKAL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 308.73 | 2.47 | 0.32% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
100%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
HIKAL Company Profile
Hikal Limited is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharmaceutical ingredients and contract research activities. The Company offers pharmaceuticals and agrochemicals.
SUNPHARMA
PE Ratio
39.92
39.92
1Y Return
1.01%
1.01%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.21
67.21
1Y Return
13.21%
13.21%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.34%
1.34%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.81
18.81
1Y Return
5.10%
5.10%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.12
29.12
1Y Return
0.46%
0.46%
Buy Reco %
72.22
72.22
HIKAL Sentiment Analysis
HIKAL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
HIKAL Stock Summary · August 2025
Hikal Ltd. reported a consolidated revenue of Rs. 380 crores for Q1 FY26, reflecting a decline from the previous year primarily due to deferred shipments in its Pharmaceutical division, which is grappling with regulatory challenges and an anticipated recovery in the coming quarters. Despite a significant drop in EBITDA margin to 6.5%, the company maintained a positive free cash flow and a stable debt-to-equity ratio, underscoring its financial resilience. Strategic shifts towards enhancing its CDMO services and diversifying into personal care and specialty chemicals are expected to drive future growth, while ongoing operational efficiency efforts aim to mitigate the impact of global market pressures. Management remains cautiously optimistic about long-term prospects, particularly with new product launches and improved capacity utilization on the horizon.
HIKAL Stock Growth Drivers
HIKAL Stock Growth Drivers
7Regulatory Compliance and Quality Achievements
Hikal Limited has successfully completed GMP audits at its Bangalore API facility by ANVISA and
Operational Efficiency and Financial Performance
In Q1 FY '26, Hikal Limited reported a positive free cash flow of Rs. 15
HIKAL Stock Challenges
HIKAL Stock Challenges
5Decline in Financial Performance
Hikal Limited reported a consolidated revenue of Rs. 380 crores for Q1 FY26, a decline
Challenges in the Pharmaceutical Division
The Pharmaceutical Division reported revenues of Rs. 203 crores with an EBIT loss of Rs.
HIKAL Forecast
HIKAL Forecasts
Price
Revenue
Earnings
HIKAL Share Price Forecast
HIKAL Share Price Forecast
2025
Current
₹252.89
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹252.89
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
HIKAL Company Revenue Forecast
HIKAL Company Revenue Forecast
2025
Current
₹1.86
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.86
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
HIKAL Stock EPS (Earnings Per Share) Forecast
HIKAL Stock EPS (Earnings Per Share) Forecast
2025
Current
₹7.36
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹7.36
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
HIKAL
HIKAL
Income
Balance Sheet
Cash Flow
Annual Normal View
HIKAL Income Statement
HIKAL Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,017.38 | 1,300.55 | 1,591.87 | 1,510.96 | 1,725.42 | 1,947.61 | 2,028.44 | 1,787.10 | 1,864.80 | 1,706.00 | ||||||||||
Raw Materials | 494.83 | 715.32 | 868.80 | 781.90 | 906.71 | 1,032.21 | 1,121.59 | 805.20 | 882.70 | 1,471.20 | ||||||||||
| Power & Fuel Cost | 85.63 | 108.41 | 132.04 | 129.99 | 147.83 | 175.46 | 186.91 | 170.20 | 168.10 | |||||||||||
| Employee Cost | 116.69 | 128.06 | 135.69 | 156.57 | 164.32 | 203.38 | 222.44 | 246.50 | 247.10 | |||||||||||
| Selling & Administrative Expenses | 43.74 | 45.90 | 52.50 | 55.57 | 64.05 | 95.21 | 107.96 | 113.60 | 110.50 | |||||||||||
| Operating & Other expenses | 78.80 | 56.67 | 102.46 | 125.48 | 114.64 | 95.91 | 127.06 | 182.10 | 123.00 | |||||||||||
EBITDA | 197.69 | 246.19 | 300.38 | 261.45 | 327.87 | 345.44 | 262.48 | 269.50 | 333.40 | 234.80 | ||||||||||
| Depreciation/Amortization | 69.14 | 85.59 | 92.88 | 82.46 | 85.25 | 95.67 | 109.01 | 117.60 | 134.40 | 151.50 | ||||||||||
| PBIT | 128.55 | 160.60 | 207.50 | 178.99 | 242.62 | 249.77 | 153.47 | 151.90 | 199.00 | 83.30 | ||||||||||
| Interest & Other Items | 48.27 | 49.12 | 58.43 | 52.42 | 36.20 | 31.22 | 48.10 | 56.40 | 75.20 | 68.60 | ||||||||||
| PBT | 80.28 | 111.48 | 149.07 | 126.57 | 206.42 | 218.55 | 105.37 | 95.50 | 123.80 | 14.70 | ||||||||||
| Taxes & Other Items | 12.54 | 34.27 | 46.01 | 42.14 | 73.28 | 58.06 | 26.99 | 25.90 | 33.00 | 4.60 | ||||||||||
| Net Income | 67.74 | 77.21 | 103.06 | 84.43 | 133.14 | 160.49 | 78.38 | 69.60 | 90.80 | 10.10 | ||||||||||
| EPS | 5.49 | 6.26 | 8.36 | 6.85 | 10.80 | 13.02 | 6.36 | 5.64 | 7.36 | 0.82 | ||||||||||
| DPS | 0.80 | 0.80 | 1.20 | 1.20 | 2.00 | 1.60 | 1.20 | 1.20 | 0.80 | 1.40 | ||||||||||
| Payout ratio | 0.15 | 0.13 | 0.14 | 0.18 | 0.19 | 0.12 | 0.19 | 0.21 | 0.11 | 1.71 |
HIKAL Company Updates
FY 2026FY 2026
Investor Presentation
Nov 13PDF
Sep 23PDF
Aug 7PDF
HIKAL Stock Peers
HIKAL Past Performance & Peer Comparison
HIKAL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Hikal Ltd | 34.34 | 2.47 | 0.32% |
| Sun Pharmaceutical Industries Ltd | 39.92 | 6.02 | 0.88% |
| Torrent Pharmaceuticals Ltd | 67.21 | 16.92 | 0.84% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
HIKAL Stock Price Comparison
Compare HIKAL with any stock or ETFCompare HIKAL with any stock or ETF
HIKAL
HIKAL Holdings
HIKAL Shareholdings
HIKAL Promoter Holdings Trend
HIKAL Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
HIKAL Institutional Holdings Trend
HIKAL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 1.12%
HIKAL Shareholding Pattern
HIKAL Shareholding Pattern
HIKAL Shareholding History
HIKAL Shareholding History
Foreign Institutions
Mutual Funds Invested in HIKAL
Mutual Funds Invested in HIKAL
No mutual funds holding trends are available
Top 5 Mutual Funds holding Hikal Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.5225% | Percentage of the fund’s portfolio invested in the stock 0.67% | Change in the portfolio weight of the stock over the last 3 months -0.25% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/69 (-6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.7389% | Percentage of the fund’s portfolio invested in the stock 0.84% | Change in the portfolio weight of the stock over the last 3 months 0.84% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/44 (+9) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3010% | Percentage of the fund’s portfolio invested in the stock 0.71% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 42/46 (-12) |
Compare 3-month MF holding change on Screener
smallcases containing HIKAL stock
smallcases containing HIKAL stock
Looks like this stock is not in any smallcase yet.
HIKAL Events
HIKAL Events
HIKAL Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.32%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.16 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
HIKAL Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.32%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.16 every year
HIKAL Upcoming Dividends
HIKAL Upcoming Dividends
No upcoming dividends are available
HIKAL Past Dividends
HIKAL Past Dividends
Cash Dividend
Ex DateEx DateSep 2, 2025
Final
Final | Div/Share: ₹0.80
Dividend/Share
₹0.80
Ex DateEx Date
Sep 2, 2025
Cash Dividend
Ex DateEx DateFeb 7, 2025
Interim
Interim | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Feb 7, 2025
Cash Dividend
Ex DateEx DateSep 4, 2024
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Sep 4, 2024
Cash Dividend
Ex DateEx DateFeb 20, 2024
Interim
Interim | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Feb 20, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Sep 18, 2023
HIKAL Stock News & Opinions
HIKAL Stock News & Opinions
Articles & Videos
Corporate
Hikal receives revision in credit ratings from ICRA
Hikal has received revision in credit ratings from ICRA as under: Long term rating - ICRA A; Stable (revised from ICRA A+; Stable) Short term rating - ICRA A2+ (revised from ICRA A1) Powered by Capital Market - Live
1 week agoCapital Market - Live
Earnings
Hikal reports consolidated net loss of Rs 34.90 crore in the September 2025 quarter
Net loss of Hikal reported to Rs 34.90 crore in the quarter ended September 2025 as against net profit of Rs 18.30 crore during the previous quarter ended September 2024. Sales declined 29.86% to Rs 316.20 crore in the quarter ended September 2025 as against Rs 450.80 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales316.20450.80 -30 OPM %2.2816.61 - PBDT-5.8056.50 PL PBT-47.0024.80 PL NP-34.9018.30 PL Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Hikal to hold board meeting
Hikal will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Hikal slides after receiving USFDA warning letter for Jigani Facility
The letter follows a regulatory inspection conducted at the site from 3rd to 7th February 2025. The company stated that it is working closely with the US FDA to resolve the issues raised and reiterated its commitment to upholding cGMP (current Good Manufacturing Practices) standards across all its manufacturing facilities. We uphold quality and compliance with utmost importance and are committed to addressing the concerns at the earliest, the company said in an official statement. As per an earlier exchange filing dated 8 February 2025, the USFDA inspection at the Jigani unit concluded with six observations. Hikal had confirmed it would address each observation and submit its response within the stipulated timeframe. In a subsequent filing dated 23 May 2025, the company informed that the inspection outcome had been classified as Official Action Indicated (OAI) by the US FDA. Despite the regulatory classification, Hikal emphasized that it does not anticipate any impact on business continuity or the supply of existing products from the Jigani facility. The company added that it remains fully committed to maintaining the highest standards of quality and compliance at all its facilities and is actively working to enhance regulatory adherence on an ongoing basis. Hikal is engaged in the business of pharmaceuticals, crop protection, and specialty chemicals. The company reported consolidated net loss of Rs 22.40 crore in Q1 FY26 as against net profit of Rs 5.10 crore reported in Q1 FY25. Revenue from operations fell 8% YoY to Rs 371.30 crore in the quarter ended 30 June 2025. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Hikal to conduct AGM
Hikal announced that the Annual General Meeting(AGM) of the company will be held on 23 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Hikal reports consolidated net loss of Rs 22.40 crore in the June 2025 quarter
Net loss of Hikal reported to Rs 22.40 crore in the quarter ended June 2025 as against net profit of Rs 5.10 crore during the previous quarter ended June 2024. Sales declined 8.05% to Rs 371.30 crore in the quarter ended June 2025 as against Rs 403.80 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales371.30403.80 -8 OPM %6.7614.36 - PBDT9.0038.70 -77 PBT-30.406.90 PL NP-22.405.10 PL Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Hikal schedules board meeting
Hikal will hold a meeting of the Board of Directors of the Company on 7 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Hikal clears ANVISA GMP audit at Bengaluru API unit
The audit, which covered multiple active pharmaceutical ingredients (APIs), was conducted from 14 April to 18 April 2025. The successful completion of the inspection reinforces Hikal's compliance with international quality standards and strengthens its position in regulated markets like Brazil. Hikal is engaged in the business of pharmaceuticals, crop protection, and specialty chemicals. The company's consolidated net profit rallied 48.08% to Rs 50.20 crore on 7.44% rise in revenue from operations to Rs 552.40 crore in Q4 FY25 over Q4 FY24. Shares of Hikal rose 0.29% to Rs 377.10 on the BSE. Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Hikal consolidated net profit rises 48.08% in the March 2025 quarter
Net profit of Hikal rose 48.08% to Rs 50.20 crore in the quarter ended March 2025 as against Rs 33.90 crore during the previous quarter ended March 2024. Sales rose 7.25% to Rs 550.00 crore in the quarter ended March 2025 as against Rs 512.80 crore during the previous quarter ended March 2024. For the full year,net profit rose 30.46% to Rs 90.80 crore in the year ended March 2025 as against Rs 69.60 crore during the previous year ended March 2024. Sales rose 4.23% to Rs 1843.50 crore in the year ended March 2025 as against Rs 1768.70 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales550.00512.80 7 1843.501768.70 4 OPM %22.4418.41 -17.8115.10 - PBDT106.0079.60 33 258.20213.10 21 PBT68.3047.30 44 123.8095.50 30 NP50.2033.90 48 90.8069.60 30 Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Hikal standalone net profit rises 48.82% in the March 2025 quarter
Net profit of Hikal rose 48.82% to Rs 50.30 crore in the quarter ended March 2025 as against Rs 33.80 crore during the previous quarter ended March 2024. Sales rose 7.25% to Rs 550.00 crore in the quarter ended March 2025 as against Rs 512.80 crore during the previous quarter ended March 2024. For the full year,net profit rose 30.79% to Rs 90.90 crore in the year ended March 2025 as against Rs 69.50 crore during the previous year ended March 2024. Sales rose 4.23% to Rs 1843.50 crore in the year ended March 2025 as against Rs 1768.70 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales550.00512.80 7 1843.501768.70 4 OPM %22.4518.39 -17.8215.09 - PBDT106.1079.50 33 258.30213.00 21 PBT68.4047.20 45 123.9095.40 30 NP50.3033.80 49 90.9069.50 31 Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 4.3%, vs industry avg of 10.03%
Over the last 5 years, market share decreased from 0.6% to 0.44%
Over the last 5 years, net income has grown at a yearly rate of 1.47%, vs industry avg of 20.02%